Shield Therapeutics PLC Notice of Results and Change in reporting currency (4851L)
September 06 2023 - 1:00AM
UK Regulatory
TIDMSTX
RNS Number : 4851L
Shield Therapeutics PLC
06 September 2023
Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Notice of interim results
Change in reporting currency
London, UK, 6 September 2023: Shield Therapeutics plc (LSE:
STX), a commercial stage pharmaceutical company focused on the
commercialisation of its innovative oral iron therapy for iron
deficiency, Accrufer(R)/Feraccru(R) (ferric maltol), will announce
its interim results for the six months ended 30 June 2023 on
Thursday 28 September 2023.
Investor presentation
CEO, Greg Madison, and CFO, Hans-Peter Rudolf, will be hosting a
live online presentation relating to the interim results via the
Investor Meet Company platform at 16.30 (BST) on Thursday 28
September 2023.
The presentation is open to all existing and potential
investors. Questions can be submitted pre-event via your Investor
Meet Company dashboard up until 09:00 (BST) the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Shield Therapeutics plc via:
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
Investors who already follow Shield Therapeutics plc on the
Investor Meet Company platform will automatically be invited.
Change in reporting currency
Reflecting the increasing importance of the Group's U.S.
operations on its financial results, Shield is also announcing that
it will change its reporting currency from Pounds Sterling to US
Dollars (USD) effective 1 January 2023.The interim results for the
six months ending 30 June 2023 will include condensed, consolidated
USD financial information for H123 and FY22. In accordance with the
relevant accounting standards, comparative historic financial
information for FY 2022 will be published in USD alongside the full
FY 2023 results in the first half of 2024.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Greg Madison, CEO +44 (0) 191 511 8500
Hans-Peter Rudolf, CFO
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Patrick Birkholm +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/ George Dollemore
/Nigel Birks/Harriet Ward +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR
Paul McManus/Lianne Applegarth/ +44 (0)20 7933 8780 or shield@walbrookpr.com
Alice Woodings
Investor Contact (US Advisor)
LifeSci Advisors, LLC
John Mullaly +1 617 429 3548 or jmullaly@lifesciadvisors.com
About Accrufer(R)/Feraccru(R)
Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable,
non-salt based oral therapy for adults with iron deficiency, with
or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of
action compared to other oral iron therapies and has been shown to
be an efficacious and well-tolerated therapy in a range of clinical
trials. More information about Accrufer(R)/Feraccru(R), including
the product label, can be found at: www.accrufer.com and
www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage pharmaceutical company focused on
the commercialisation of Accrufer(R)/Feraccru(R) (ferric maltol),
an innovative oral iron therapy for iron deficiency differentiated
from other irons by its efficacy, broad label and well-tolerated
formulation. The Group has launched Accrufer(R) in the US with an
exclusive, multi-year collaboration agreement with Viatris, Inc.
Feraccru(R) is commercialised in the UK and European Union by
Norgine B.V., that also have the marketing rights in Australia and
New Zealand. Shield also has an exclusive license agreement with
Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and
commercialisation of Accrufer(R) / Feraccru(R) in China, Hong Kong,
Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of
Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer(R)/Feraccru(R) has patent coverage until the
mid-2030s
Accrufer(R)/Feraccru(R) are registered trademarks of the Shield
Group
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOREAFNSEEADEAA
(END) Dow Jones Newswires
September 06, 2023 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2023 to Apr 2024